H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of Spectral AI with a Buy rating and $3.50 price target. Spectral AI is a commercial-stage medical diagnostics company focused on developing a novel imaging system that includes a predictive artificial intelligence solution to generate more accurate and faster treatment decisions in wound care, the analyst tells investors in a research note. The firm believes Spectral AI has a “disruptive device” that can potentially change the wound treatment paradigm; at a market cap of $33M it is an attractive investment for long-term investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDAI:
- Spectral AI Tackles Market Manipulation Concerns
- Spectral AI continues support of naked short selling inquiry
- Spectral AI Continues Support of Naked Short Selling Inquiry
- Spectral AI announces collaboration with PolyNovo
- Spectral AI Announces Collaboration with Global Wound Care Company PolyNovo to Introduce DeepView System for Burn Indication to Australian Market